ENPHILBRAY
Live / Applied — Third extension granted (statement of use) (as of 05 Mar 2026)
What this means for you
Not registered yet, but its 08 May 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97925213
- Mark type
- Stylized text
- Filed
- 08 May 2023
- Published for opposition
- 27 Aug 2024
- Attorney of record
- Alexandra Kochian
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the prevention and treatment of cardiovascular diseases and diseases of the central nervous system; pharmaceutical preparations for the treatment of cancer, thrombosis, and respiratory diseases; pharmaceutical preparations for the treatment of rare diseases notably lysosomal storage disorders and autosomal dominant polycystic kidney disease; pharmaceutical preparations for the prevention and treatment of infectious diseases, namely, viral and bacterial infections
Owner
- Genzyme Corporation, Cambridge, MA, US
- Genzyme Corporation, Cambridge, MA, US
Prosecution history
- 06 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 Mar 2026 — SOU EXTENSION 3 GRANTED
- 05 Mar 2026 — SOU EXTENSION 3 FILED
- 05 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 28 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Aug 2025 — SOU EXTENSION 2 GRANTED
- 27 Aug 2025 — SOU EXTENSION 2 FILED
- 27 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 26 Jun 2025 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
- 26 Jun 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 26 Jun 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 26 Jun 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 02 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Mar 2025 — SOU EXTENSION 1 GRANTED
- 28 Feb 2025 — SOU EXTENSION 1 FILED